TKT’s Former CEO Settles SEC Fraud Charges For $1.2 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Charges date to 2005 for misleading statements made about Replagal; Transkaryotic Therapies was later acquired by Shire.
You may also be interested in...
Shire/TKT Merger Deal Focuses On Dynepo Rights In Europe
Shire will promote TKT's Dynepo in Europe with part of its 200-person Fosrenol sales force. European rights to the erythropoietin product were one of the critical components to the $1.6 bil. acquisition. The deal also brings Shire two products in development.
SEC’s TKT Investigation
Securities & Exchange Commission staff has preliminarily decided to recommend taking action against Transkaryotic Therapies for securities law violations, the company said
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.